Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Berger

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 2006
Human antibodies for immunotherapy development generated via a human B cell hybridoma technologyJian Li, Tao Sai, Marc Berger, et al.
Cancer Research|January 26, 2022
Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at DiagnosisAntonin Marchais, Maria Eugenia Marques da Costa, Bastien Job, et al.
Contemporary Clinical Trials|July 17, 2012
Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United StatesKenneth G Saag, Penny E Mohr, Laura Esmail, et al.
Critical Care (London, England)|August 18, 2021
Machine learning identifies ICU outcome predictors in a multicenter COVID-19 cohortHarry Magunia, Simone Lederer, Raphael Verbuecheln, et al.
Leukemia|January 23, 2021
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trialFrancois Guilhot, Françoise Rigal-Huguet, Joëlle Guilhot, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 2006
Human antibodies for immunotherapy development generated via a human B cell hybridoma technologyJian Li, Tao Sai, Marc Berger, et al.
Cancer Research|January 26, 2022
Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at DiagnosisAntonin Marchais, Maria Eugenia Marques da Costa, Bastien Job, et al.
Contemporary Clinical Trials|July 17, 2012
Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United StatesKenneth G Saag, Penny E Mohr, Laura Esmail, et al.
Critical Care (London, England)|August 18, 2021
Machine learning identifies ICU outcome predictors in a multicenter COVID-19 cohortHarry Magunia, Simone Lederer, Raphael Verbuecheln, et al.
Leukemia|January 23, 2021
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trialFrancois Guilhot, Françoise Rigal-Huguet, Joëlle Guilhot, et al.
Pageof 6